Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02392468 · ClinicalTrials.gov registry record · Phase 1
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT02392468 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 61 participants.
The verdict
NCT02392468, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease, or age comparable healthy volunteers.
Interventions
- DRUG Placebo matching BI 409306 25 mg
- DRUG Placebo matching BI 409306 50 mg
- DRUG BI 409306 25 mg
- DRUG BI 409306 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-04-15 |
| Est. Completion | 2017-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02392468
The ClinicalTrials.gov registry entry for NCT02392468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo matching BI 409306 25 mg is the first listed.
NCT02392468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02392468 about?
NCT02392468 is a clinical study titled "Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers". Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease, or age comparable healthy volunteers.
What is the current status of trial NCT02392468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2015-04-15. Estimated completion is 2017-08-10.
What interventions are being tested in trial NCT02392468?
The interventions under investigation include: Placebo matching BI 409306 25 mg (DRUG), Placebo matching BI 409306 50 mg (DRUG), BI 409306 25 mg (DRUG), BI 409306 50 mg (DRUG).
Who is sponsoring clinical trial NCT02392468?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.